![]() |
市場調查報告書
商品編碼
2179121
人工智慧驅動的臨床試驗患者配對市場預測至2034年:全球分析(按組件、解決方案類型、技術、部署模式、應用和區域分類)AI-Driven Clinical Trial Patient Matching Market Forecasts to 2034 - Global Analysis By Component (Software and Services), Solution Type, Technology, Deployment Mode, Application and By Geography |
||||||
根據 Stratistics MRC 的數據,全球人工智慧驅動的臨床試驗患者匹配市場預計將在 2026 年達到 17 億美元,並在預測期內以 20.6% 的複合年成長率成長,到 2034 年達到 76 億美元。
人工智慧驅動的臨床試驗患者配對市場涵蓋了能夠分析電子健康記錄、基因組資訊和臨床試驗入組合格的智慧解決方案,旨在識別合適的受試者。對快速招募患者、提高臨床試驗入組效率以及個人化臨床研究日益成長的需求正在推動市場發展。自然語言處理、機器學習和真實世界數據分析的融合,實現了自動化的合格篩選,並將患者與臨床試驗精準配對。數位醫療基礎設施的日益普及,也為先進的臨床試驗參與者招募平台創造了機會。
對高效的患者招募和臨床試驗註冊的需求日益成長。
對高效能患者招募和臨床試驗入組的需求日益成長,推動了市場成長。製藥公司和研究機構面臨著在複雜的臨床研究方案中識別合格受試者的挑戰。人工智慧驅動的配對平台透過分析電子健康記錄、病歷和合格要求,更有效率地識別合適的候選人。減少招募延遲和提高試驗入組率的日益重視正在推動這項技術的應用。自然語言處理、預測分析和臨床數據互通性的進步進一步刺激了對智慧型患者識別和入組解決方案的需求。
臨床資料互通性受限以及嚴格的病患隱私要求
臨床數據互通性的局限性以及嚴格的患者隱私要求正在限制市場成長。人工智慧驅動的患者匹配系統需要存取全面的電子健康記錄、基因組資訊和臨床研究資料庫。醫療資訊系統的碎片化和不一致的文檔標準使資料整合和自動合格評估變得複雜。遵守有關患者知情同意、資料保護和臨床研究的法規也增加了部署的複雜性。高昂的整合成本、有限的代表性訓練資料集以及對演算法透明度的擔憂可能會進一步減緩醫療機構的採用速度。
精準醫療的擴展及其與人工智慧驅動的基因組臨床試驗的結合。
精準醫療和人工智慧驅動的基因組臨床試驗匹配技術的擴展帶來了巨大的成長機會。製藥公司和醫療機構正日益採用以生物標記為導向的臨床試驗,這類試驗需要精準識別合格的受試者。人工智慧平台能夠結合基因組圖譜、病歷和真實世界臨床數據,幫助推薦個人化的臨床試驗。對癌症研究和罕見疾病治療投入的增加正在推動這項技術的應用。多模態人工智慧、知識圖譜和聯邦學習技術的進步有望提升匹配能力,並擴大臨床研究的參與範圍。
演算法偏差和網路安全風險影響患者匹配的可靠性
演算法偏差和網路安全風險會影響患者配對的可靠性,為市場發展帶來重大挑戰。人工智慧平台依賴敏感的醫療資訊和複雜的預測模型,因此面臨未授權存取、資料外洩和不準確的合格評估等風險。不完整或缺乏代表性的資料集可能導致有偏見的患者推薦,並限制患者參與臨床試驗。監管機構對自動化臨床決策支援的審查也會阻礙其應用。與傳統受試者招募服務的競爭以及整合到臨床工作流程的不確定性也可能進一步限制其應用。
新冠疫情凸顯了高效識別受試者和靈活招募研究參與者的必要性,加速了人們對人工智慧驅動的臨床試驗患者匹配技術的興趣。醫療服務中斷、旅行限制以及試驗場所准入受限,使得傳統臨床試驗的招募工作異常艱難。製藥公司和研究機構日益尋求數位化招募、電子健康記錄(EHR)篩選和遠端合格評估,以維持研究的連續性。對虛擬臨床研究和數據驅動招募技術的投入增加,推動了創新。疫情後時代分散式試驗模式的普及,也印證了對智慧患者匹配平台的持續需求。
在預測期內,軟體領域預計將佔據最大的市場佔有率。
在預測期內,軟體領域預計將佔據最大的市場佔有率,這主要得益於對自動化合格篩選、臨床數據整合和智慧受試者招募解決方案日益成長的需求。製藥公司、醫院和研究機構需要複雜的軟體來分析醫療記錄、解讀試驗標準並識別合適的受試者。電子健康記錄和基於雲端的臨床研究平台的日益普及正在推動軟體投資的成長。自然語言處理、預測分析和可互通的健康數據系統的進步也進一步促進了該領域的成長。
預計在預測期內,生成式人工智慧和大規模語言模型領域將呈現最高的複合年成長率。
在預測期內,生成式人工智慧和大規模語言建模領域預計將呈現最高的成長率,這主要得益於對複雜臨床試驗合格標準和自動解讀非結構化醫療記錄的需求不斷成長。大規模語言模型可以幫助提取相關的患者特徵、總結臨床資訊並識別潛在的試驗對象。對人工智慧驅動的臨床研究投入的增加正在推動創新。醫學語言模型、基於搜尋的檢驗和人工監督篩選的進步有望加速這些技術在臨床受試者招募平台中的應用。
在預測期內,北美預計將佔據最大的市場佔有率,這得益於其完善的臨床研究基礎設施、製藥業的巨額投資以及電子健康記錄的廣泛應用。美國正透過領先的醫療機構、生物技術公司和臨床研究組織來推動區域發展,這些機構正在採用人工智慧驅動的受試者招募技術。對精準醫療、基因組檢測和真實世界數據分析的投資不斷增加,也推動了這項技術的應用。醫療服務提供者、製藥公司和技術開發商之間的合作,進一步推動了區域對智慧受試者匹配解決方案的需求。
在預測期內,亞太地區預計將呈現最高的複合年成長率,這主要得益於臨床研究活動的拓展、醫療數位化進程的推進以及藥物研發投入的增加。中國、印度、日本和韓國正在發展電子健康記錄記錄基礎設施,並推動技術驅動的臨床研究計畫。不同患者群體對高效招募受試者的需求不斷成長,推動了平台應用。政府主導的醫療現代化以及醫院、研究機構和技術提供者之間的夥伴關係,預計將加速人工智慧驅動的患者匹配解決方案在亞太地區的普及。
According to Stratistics MRC, the Global AI-Driven Clinical Trial Patient Matching Market is accounted for $1.7 billion in 2026 and is expected to reach $7.6 billion by 2034 growing at a CAGR of 20.6% during the forecast period. The AI-Driven Clinical Trial Patient Matching Market encompasses intelligent solutions that analyze electronic health records, genomic information, and clinical trial eligibility criteria to identify suitable research participants. Increasing demand for faster patient recruitment, improved trial enrollment, and personalized clinical research is supporting market development. Integration of natural language processing, machine learning, and real-world data analytics enables automated eligibility screening and accurate patient-to-trial matching. Growing adoption of digital healthcare infrastructure creates opportunities for advanced clinical recruitment platforms.
Increasing demand for efficient patient recruitment and clinical trial enrollment
Increasing demand for efficient patient recruitment and clinical trial enrollment is driving market growth. Pharmaceutical companies and research organizations face challenges identifying eligible participants within complex clinical research protocols. AI-driven matching platforms analyze electronic health records, medical histories, and eligibility requirements to identify suitable candidates more efficiently. Growing emphasis on reducing recruitment delays and improving trial participation encourages technology adoption. Advancements in natural language processing, predictive analytics, and clinical data interoperability further strengthen demand for intelligent patient identification and enrollment solutions.
Limited clinical data interoperability and stringent patient privacy requirements
Limited clinical data interoperability and stringent patient privacy requirements restrain market growth. AI-driven patient matching systems require access to comprehensive electronic health records, genomic information, and clinical research databases. Fragmented healthcare information systems and inconsistent documentation standards complicate data integration and automated eligibility assessment. Compliance with patient consent, data protection, and clinical research regulations increases implementation complexity. High integration costs, limited access to representative training datasets, and concerns regarding algorithm transparency may further delay adoption across healthcare institutions.
Expansion of precision medicine and AI-enabled genomic trial matching
Expansion of precision medicine and AI-enabled genomic trial matching presents significant growth opportunities. Pharmaceutical sponsors and healthcare providers are increasingly adopting biomarker-driven clinical trials that require precise identification of eligible participants. AI-powered platforms can combine genomic profiles, medical histories, and real-world clinical data to support personalized trial recommendations. Growing investment in oncology research and rare disease therapies encourages adoption. Advancements in multimodal artificial intelligence, knowledge graphs, and federated learning are expected to improve matching capabilities and expand clinical research participation.
Algorithmic bias and cybersecurity risks affecting patient matching reliability
Algorithmic bias and cybersecurity risks affecting patient matching reliability pose significant challenges to market development. AI-driven platforms depend on sensitive healthcare information and complex predictive models, creating exposure to unauthorized access, data breaches, and inaccurate eligibility assessments. Incomplete or unrepresentative datasets may generate biased patient recommendations and reduce trial accessibility. Regulatory scrutiny surrounding automated clinical decision support can complicate implementation. Competition from conventional recruitment services and uncertainty regarding clinical workflow integration may further restrict adoption.
The COVID-19 pandemic accelerated interest in AI-driven clinical trial patient matching technologies by highlighting the need for efficient participant identification and flexible research recruitment. Healthcare disruptions, travel restrictions, and reduced site access complicated conventional clinical trial enrollment. Pharmaceutical companies and research organizations increasingly explored digital recruitment, electronic health record screening, and remote eligibility assessment to maintain research continuity. Growing investment in virtual clinical research and data-driven recruitment technologies encouraged innovation. Post-pandemic adoption of decentralized trial models has supported continued demand for intelligent patient matching platforms.
The software segment is expected to be the largest during the forecast period
The software segment is expected to account for the largest market share during the forecast period due to increasing demand for automated eligibility screening, clinical data integration, and intelligent patient recruitment solutions. Pharmaceutical sponsors, hospitals, and research organizations require advanced software to analyze medical records, interpret trial criteria, and identify suitable participants. Growing adoption of electronic health records and cloud-based clinical research platforms supports software investment. Advancements in natural language processing, predictive analytics and interoperable healthcare data systems further strengthen segment growth.
The generative AI & large language models segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the generative AI & large language models segment is predicted to witness the highest growth rate due to increasing demand for automated interpretation of complex clinical trial eligibility criteria and unstructured medical records. Large language models can assist with extracting relevant patient characteristics, summarizing clinical information, and identifying potential trial matches. Growing investment in AI-enabled clinical research encourages innovation. Advancements in medical language models, retrieval-based validation, and human-supervised screening are expected to accelerate adoption across clinical recruitment platforms.
During the forecast period, North America is expected to hold the largest market share due to established clinical research infrastructure, substantial pharmaceutical investment, and widespread adoption of electronic health records. The United States leads regional development through advanced healthcare institutions, biotechnology companies, and clinical research organizations implementing AI-driven recruitment technologies. Growing investment in precision medicine, genomic testing, and real-world data analytics supports adoption. Collaboration among healthcare providers, pharmaceutical sponsors, and technology developers further strengthens regional demand for intelligent patient matching solutions.
Over the forecast period, Asia Pacific is anticipated to exhibit the highest CAGR, supported by expanding clinical research activities, increasing healthcare digitization, and growing investment in pharmaceutical development. China, India, Japan, and South Korea are advancing electronic health record infrastructure and technology-enabled clinical research programs. Increasing demand for efficient recruitment across diverse patient populations encourages platform deployment. Government-supported healthcare modernization and partnerships among hospitals, research organizations, and technology providers are expected to accelerate regional adoption of AI-driven patient matching solutions.
Key players in the market
Some of the key players in the AI-Driven Clinical Trial Patient Matching Market include Tempus AI, Inc., TriNetX, LLC, IQVIA Holdings Inc., Medidata Solutions, Inc., ConcertAI, LLC, Mendel, Massive Bio, Inc., Antidote Technologies, Inc., Trialbee AB, Triomics, Inc., Paradigm Health, Inc., Reify Health, Inc., Clinerion AG, HealthMatch, Komodo Health, Inc., myTomorrows, TrialX, Inc., and HEALWELL AI Inc.
In October 2026, Tempus AI, Inc. expanded its strategic collaboration with Bristol Myers Squibb through a multi-year agreement to provide multimodal oncology datasets and access to its AI-powered Lens Platform. The collaboration supports advanced clinical data analysis, biomarker research, and oncology drug development, strengthening the data infrastructure relevant to precision patient identification.
In April 2026, Massive Bio, Inc. announced a collaboration with OpenAI to advance automated clinical trial eligibility interpretation and patient pre-screening. The initiative converts complex clinical trial protocols into machine-readable criteria, enabling faster identification of potentially eligible oncology and hematology patients.
In April 2026, Massive Bio, Inc. also published a prospective study evaluating its neuro-symbolic, multi-agent AI platform across 3,804 cancer patients. The study reported more than 17,000 oncologist-confirmed trial matches and approximately fourfold faster matching compared with conventional screening methods.
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.